According to Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, this new R&D model is centered on the real needs of patients, the development of scientific networks and openness toward outside entities to strengthen creativity, and a flexible and entrepreneurial approach to research.
To implement this new R&D model, sanofi-aventis will group researchers in more productive structures and engage in recruiting and training to adapt the profiles and skills of its collaborators to the demands of these mutations.
To anticipate the consequences of a profound and continuous change in the pharmaceutical environment generated by a veritable revolution in biopharmaceutical research and to maintain its innovative capacities, the Group intends to set in place the most effective R&D organization in the pharmaceutical industry by 2013.<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
